The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Treating relapsed myeloma outside of the use of T-cell redirected therapies
P. Joy Ho, MBBS, DPhil, FRACP, FRCPA, FFSc(RCPA), Royal Prince Alfred Hospital & University of Sydney, Sydney, Australia, discusses the treatment of relapsed multiple myeloma (MM) outside of the use of T-cell redirected therapies, noting that treatment decisions are heavily influenced by patients’ refractoriness to lenalidomide, proteasome inhibitors, and anti-CD38 antibodies. Prof. Ho emphasizes the efficacy of anti-CD38 antibody triplet combinations for lenalidomide-refractory patients, while other options, including carfilzomib- or pomalidomide-based combinations and emerging therapies like cereblon E3 ligase modulators (CELMoDs), may be suitable for those also refractory to anti-CD38 antibodies. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
